Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup ; volume:39 ; number:6 ; day:3 ; month:5 ; year:2022 ; pages:2984-2998 ; date:6.2022
Advances in therapy ; 39, Heft 6 (3.5.2022), 2984-2998, 6.2022
- Urheber
-
Okada, Annabelle A.
Takahashi, Kanji
Ohji, Masahito
Moon, SungChul Charles
Machewitz, Tobias
Sasaki, Koji
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-022-02162-w
- URN
-
urn:nbn:de:101:1-2022072223104482759932
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Okada, Annabelle A.
- Takahashi, Kanji
- Ohji, Masahito
- Moon, SungChul Charles
- Machewitz, Tobias
- Sasaki, Koji
- SpringerLink (Online service)
Ähnliche Objekte (12)
One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
Result of intravitreal aflibercept injection for myopic choroidal neovascularization
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results
Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
Result of intravitreal aflibercept injection for myopic choroidal neovascularization
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results
Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
Result of intravitreal aflibercept injection for myopic choroidal neovascularization
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results
Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD